Novo Nordisk's November Test: JPMorgan's Neutral Stance Meets Lilly's Retatrutide Challenge
Published on 10/28/2026 at 22:01 | Editorial boerse-global.de
Novo Nordisk investors face a split-screen problem. The near-term question is whether the Danish drugmaker can beat expectations when it reports third-quarter and nine-month 2026 results before market open on 4 November 2026. The longer-term question is how much damage Eli Lilly's experimental retatrutide does to Novo's competitive standing. Those two clocks are ticking at different speeds, and the market has yet to decide which one matters more.
JPMorgan analyst Richard Vosser expects adjusted revenue and adjusted operating profit above consensus at the upcoming print. Yet the house stays at "Neutral" with a price target of 275 DKK. That combination carries the real message: an earnings beat and a constructive valuation are not the same thing. If analyst estimates already anticipate a better trajectory, confirmation of that trajectory creates limited new grounds for a more favourable view.
The Bar Is the Gap to Expectations, Not the Guidance Itself
A possible upgrade to full-year targets would not be enough on its own. Consensus already largely prices in such a step, according to JPMorgan. The decisive test is therefore the distance between guidance and what is already baked in — not the guidance headline. Investors should read the results and the annual outlook together. A stronger business would justify additional confidence mainly if it exceeded the expectation Vosser describes. If Novo merely delivers the anticipated guidance step, the report would confirm the known picture rather than counterbalance Lilly's study data.
The immediate trigger for the debate is the head-to-head TRANSCEND-T2D-2 trial, which studied 1,298 adults with type-2 diabetes over 80 weeks. Lilly's not-yet-approved compound produced greater weight loss and a larger reduction in blood sugar than Novo's Ozempic at its highest approved dose. Average weight loss reached 19.5% and 20.9% on the two retatrutide doses studied, against 9.4% on Ozempic. HbA1c fell by an average of 2.2 percentage points on both retatrutide doses, compared with 1.8 points on Ozempic.
Tolerability demands separate scrutiny. Gastrointestinal complaints were the most common side effects. Discontinuations due to adverse events ran at 4.8% and 7.9% on retatrutide, versus 2.7% on Ozempic — greater efficacy came with higher dropout rates. Full results are due to be presented at an upcoming medical conference and published scientifically. Reuters also reported that retatrutide improved certain cardiovascular risk factors more than Ozempic. Citi reads the results at first glance as negative for Novo and sees intensified competition in obesity and type-2 diabetes, though the bank keeps its neutral rating.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
What a Stronger Business Would and Wouldn't Buy
The positive scenario does not require Novo to match the new competitor clinically overnight. It would initially suffice for the business to prove more robust than already expected, giving investors reason to distinguish more clearly between today's operations and a possible later loss of competitive ground. Development status matters here: retatrutide is not approved, and Lilly plans to file for US approval next year, according to Reuters. Superiority reported today does not mean existing treatments will be swapped out immediately, and a filing would not yet be an approval.
Novo is meanwhile assembling additional data for its own portfolio. The company announced new results on semaglutide and the investigational drug efruxifermin for The Liver Meeting in Denver, running 5 to 9 November. These include a retrospective comparison with resmetirom in MASH as well as analyses from ESSENCE. Such presentations could round out the assessment of Novo's own development prospects if the results convince. The announcement alone, however, proves no additional therapeutic or economic benefit. In the positive scenario, a stronger current business and meaningful new research data would arrive together.
Novo can also point to a post-hoc analysis of the Phase 3 REDEFINE 1 trial. The magnitude is not the whole story: the analysis covers a female subgroup and was conducted retrospectively. Investors should read it as a specific efficacy signal, not as a direct rebuttal to Lilly's comparison with Ozempic. Weight loss in the placebo group was 3%; a 22.7% reduction had previously been reported for the full study population. The key question is how far the strong subgroup result can be extrapolated to the broader assessment of CagriSema. The Lilly comparison does not answer that — it involves a different investigational drug, a different comparator and explicitly adults with type-2 diabetes.
Why the Comparison Cuts Both Ways
The bear case rests on the character of Lilly's study. A direct comparison with Ozempic carries particular weight for competitive assessment, and Lilly reported advantages in both blood-sugar control and weight loss — the signal is not confined to a single endpoint. Against that stands Novo's retrospective subgroup analysis. Treating its result as an immediately comparable efficacy proof would overreach; equally, deriving a proven inferiority of CagriSema from the Ozempic comparison would be too short a leap. The genuine risk is an unfavourable weighting of the evidence, in which Lilly's head-to-head data dominates perception while Novo's subgroup finding carries less conviction. That would weigh on the view of the competitive position without describing a settled commercial outcome.
A constructive reading remains possible as long as investors value CagriSema as a development prospect in its own right. Good CagriSema data would not refute Lilly's result, but they could stop a single competitor comparison from becoming the entire valuation of Novo Nordisk. That scenario needs no claim of superiority over retatrutide — only that investors acknowledge the positive finding while respecting its limited reach. If sentiment instead tilts toward a broad Lilly advantage, pressure on the shares is likely to build. Both scenarios hinge on not equating different studies prematurely.
For Novo, the risk stays substantial: should Lilly's data prove convincing in full publication and later support an approval, competitive pressure could rise further. A good quarterly report would then be only short-term relief. The sequence into November is clear. First the business must convince; then the announced data must show what additional perspectives the company's own portfolio offers.
Ad
Novo Nordisk Stock: New Analysis - 28 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
